Quantum-Si Incorporated Stock Price, News & Analysis

Quantum-Si (Nasdaq: QSI), a proteomics technology company, has announced the granting of 237,068 restricted stock units (RSUs) to new employees as inducement awards. The grants were made under the company's 2023 Inducement Equity Incentive Plan and approved by the Compensation Committee of QSI's Board of Directors.

The RSUs will follow a vesting schedule with 25% vesting on September 20, 2026, followed by the remaining amount vesting in 12 equal quarterly installments. The grants comply with Nasdaq Listing Rule 5635(c)(4) and are specifically designed for new hires who were not previously QSI employees.

Quantum-Si (Nasdaq: QSI), a proteomics technology company specializing in single-molecule protein detection, announced its participation in the upcoming UBS Precision Medicine Frontiers Summit. The event will take place at the Waldorf Astoria Monarch Beach Resort & Club in Dana Point, CA, from August 13-14, 2025.

CEO Jeff Hawkins and CFO Jeff Keyes will be available for one-on-one meetings on August 14. Additionally, Jeff Hawkins will participate in the New Dimensions in Proteomics and Cellular Research panel from 8:15 - 8:50 AM PDT on the same day.

Quantum-Si (Nasdaq: QSI), a proteomics technology company, reported its Q2 2025 financial results with revenue of $591,000 and a gross margin of 59%. First half 2025 revenue reached $1.4 million, showing a 33% increase year-over-year.

The company completed a $50 million capital raise through a registered direct offering, extending their cash runway into Q2 2028. Development programs remain on track, including the Proteus™ platform, v4 Sequencing Kit (Q3 2025 launch), and v3 Library Preparation Kit (Q4 2025 launch). However, NIH funding challenges have impacted capital sales, leading to new instrument acquisition options.

Q2 2025 saw a net loss of $28.8 million compared to $23.1 million in Q2 2024. Cash position stands at $214.2 million as of June 30, 2025.

Quantum-Si (Nasdaq: QSI), a proteomics technology company specializing in single-molecule protein analysis, has announced its participation in the upcoming Canaccord Genuity 45th Annual Growth Conference. The event will take place at the InterContinental Boston Hotel from August 12-14, 2025.

The company's leadership, including President and CEO Jeff Hawkins and CFO Jeff Keyes, will conduct one-on-one meetings and participate in a fireside chat on August 12, 2025 at 4:00 PM ET. Investors can access the webcast through the company's website in the Investors section.

Quantum-Si (Nasdaq: QSI), a proteomics technology company focused on single-molecule protein analysis, has scheduled its second quarter 2025 financial results announcement for August 5, 2025.

The company will host a conference call at 4:30 PM ET on the same day, featuring CEO Jeff Hawkins and CFO Jeff Keyes. Investors can access the call through a live webcast on Quantum-Si's website or register for a personalized dial-in option.

Quantum-Si (Nasdaq: QSI), a proteomics technology company, has announced a $50 million registered direct offering of common stock. The company will sell 29,940,119 shares at $1.67 per share to a single institutional investor.

The offering is expected to close around July 8, 2025, subject to customary conditions. A.G.P./Alliance Global Partners is serving as the sole placement agent. The proceeds will be used for working capital and general corporate purposes. The offering is made through an effective shelf registration statement on Form S-3.

Quantum-Si (Nasdaq: QSI) has announced the placement of its Platinum® Pro instrument at the Broad Institute, expanding access to single-molecule protein sequencing capabilities in the Greater Boston life science ecosystem.

The collaboration aims to support scientific innovation across oncology, therapeutics, and biomedical research. Researchers will have access to advanced applications including high-resolution protein identification and protein barcoding for multiplexed screening and protein engineering applications.

Quantum-Si (Nasdaq: QSI) announces its participation in a GenomeWeb webinar titled 'From Raw to Reusable: Considerations for Data Integration and Real-World Standardization in Proteomics' scheduled for June 20, 2025. The one-hour virtual event will feature expert speakers from Quantum-Si, DNAnexus, Olink (Thermo Fisher Scientific), and Northwestern University's Proteomics Center of Excellence. The webinar will focus on crucial strategies for improving proteomics data management, including data accessibility, integration, and standardization across platforms. Key topics include metadata annotation best practices, cross-study dataset normalization, and participation in global standardization initiatives. The event aims to provide valuable insights for researchers, data scientists, and bioinformaticians in the proteomics field.

Quantum-Si (Nasdaq: QSI) announces that Liberate Bio's Director of Platform, Melissa Deck, will present at the Festival of Genomics & Biodata Boston on June 24, 2025. The presentation titled 'Precision Proteomics: Advancing Drug Development with Next-Gen Protein Sequencing' will showcase how QSI's Platinum Pro instrument is being used for protein analysis through single-molecule detection. The talk will highlight protein barcoding applications for nucleic acid-LNP therapeutic development, including single-molecule protein sequencing on a benchtop platform, proteomics and genomics integration, and multiplexed protein screening. Deck brings extensive experience in CRISPR/Cas9 editing, gene therapy, and LNP screening from her leadership roles in biotech and pharma.